SPHINGOMYELINASE COMPOSITIONS AND USE THEREOF

Abstract: The use of sphingomyelinase to increase the levels of skin and mucosal ceramides, as well as dermatological and cosmetic compositions containing same which are suitable for topical application are disclosed.

Description: SPHINGOMYELINASE COMPOSITIONS AND USE THEREOF The present invention relates to the use of sphingomyelinase to increase the levels of skin and mucosal ceramides, and dermatological and cosmetic compositions suitable for topical application containing same. Ceramide (N-acylsphingosine) is a lipid metabolite which has recently been proposed as an important intracellular messenger released inside the cell within a few hours of stimulation with various agents or as a result of serum deprivation, and is related to cell blockade in the GO/Gl phase and apoptosis. Ceramide is currently regarded as a second messenger in the context of the sphingomyelin signal transduction pathway. It is released by sphingomyelin as a result of the effect of sphingomyelinases, which are forms of phospholipase C specific for sphingomyelin. Inside the cells, ceramide can influence growth and differentiation, regulate protein secretion, induce DNA fragmentation and apoptosis, and increase the synthesis and secretion of cytokines. The molecular mechanisms underlying these various different actions are as yet not entirely known. More is known, on the other hand, about extracellular agonists which cause the release of ceramide. Hydrolysis of sphingomyelin occurs rapidly after exposure of the cells to exogenous sphingomyelinase or to agonists which activate endogenous sphingomyelinases. Such agonists include TNF-α, Fas ligand, interleukin 1-/3, IFN-γ, lα,25-dihydroxyvitamin D3 and NGF. Surprisingly, we have now found that sphingomyelinase also acts as agonist in bringing about the release of ceramide into skin and mucosa. The importance of ceramide in the skin metabolism shall be clearly apparent from what follows here below. The main cellular constituents of the epidermis are keratinocytes, melanocytes, Langerhans cells, fibroblasts, endothelial cells and macrophages. Mono- and polymorphonuclear leukocytes can infiltrate the skin in the course of inflammation or tumours. The intracellular space, on the other hand, consists mainly of neutral lipids, glyco- proteins, protein degradation products, desmosomes, active enzymes, products of sebaceous glands and ceramides. As long as this "bricks and mortar" structure is intact, the skin is endowed with both a protective layer and a selectively permeable filter. During the differentiation process of the epidermis, which starts with cell division in the basal layers and ends with the death of keratinocytes and the development of the lipid barrier, the cells modify their lipid synthesis capability. The result is that the basal layer of the epidermis is characterized by phospholipids and cholesterol, whereas the outermost layer is characterized by cholesterol, free fatty acids, and, above all, ceramides. The lipids of the horny layer, the main component of which consists of sphingolipids, play a crucial role in maintaining the permeability barrier of the epidermis to water. The sphingolipids are extruded from the lamellar bodies of the granular cells of the epidermis. Ceramides (sphingolipids), which make up 43- 46% of the horny layer, are the main polar lipids of the horny layer and play a fundamental role in the barrier function of the skin against water leakage in cell adhesion and in the differentiation of the epidermis. Literature data indicate that ceramides are synthesised de noυo in the epidermis via phospholipid-like intermediates. They are present in fairly high concentrations in the horny layer (up to 40% of total lipids). Like the appearance of the surface of the skin, its functional properties also undergo changes with ageing. Ageing skin is characterized by a reduced water content in the horny layer associated with reduced transdermal leakage of water. It has been shown that the ceramide 2: sphingolipid ratio decreases with age. The drop in ceramide associated with ageing may be responsible for the dehydration of the skin which is observed in the course of ageing. In addition, abnormal ceramide levels (deficiencies) have been detected in atopic eczema, dermatosis and dermatitis, in particular atopic dermatitis, and psoriasis. Recently, an inborn deficiency of ceramide 1 has been found in autosomal recessive sphingolipidosis. Equally well known are generalised forms of sphingolipidosis such as Fabry's disease, Gaucher's disease and Tay-Sachs disease. Sjδgren-Larsson syndrome is associated with a deficiency of ceramide 1 and 6 with attendant destruction of the normal skin barrier. In the light of the foregoing, it is obviously useful to maintain high levels of ceramide in the skin. It will additionally be understood that the use of sphingomyelinase proves advantageous also at mucosal level. There are currently available on the market numerous products containing ceramides obtained by extraction methods or synthesis and used in dermatology and cosmetics. The topical external apphcation of ceramides is proposed for remodelling the cutaneous lipid barrier altered by ageing, drugs, detergents, physical agents, etc. Such exogenous administration does not allow for the possibility that there may be qualitative and/or quantitative variations in ceramide due to age and anatomical site, seasonal factors and diseases. Clearly, then, the exogenous administration of ceramide acts only in an additive sense (endogenous + exogenous ceramide) and not in a modulatory sense (variations in ceramide according to season, anatomical site, possible disease processes in progress, etc.). Surprisingly, we have now found that high levels of neutral, but not acid, sphingomyelinase are present in the cells, and that sphingomyelinase is capable of inducing the generation of ceramide in the skin and mucosa. Consequently, one object of the present invention is to provide for the use of sphingomyelinase to produce dermatological or cosmetic compositions suitable for topical application in order to increase the level of ceramides in the skin and mucosa. According to the invention, the sphingomyeUnase is preferably extracted from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof. Lactic bacteria should preferably be chosen from among the following: Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catena for me, Lactobacillus cellobiosus, Lactobacillus crispatus, Lactobacillus curυatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudo- catenulatum, Bifidobacterium pseudolongum, Steptococcus lactis, Streptococcus raffinolactis and Streptococcus thermophilus. According to a preferred embodiment of the invention, the cells are used in the form of lyophilized or sonicated cells. According to the present invention, the sphingomyeUnase can furthermore be used as a cutaneous permeation or absorption enhancer, either alone or in admixture with other enhancers, for preparing pharmaceutical or cosmetic compositions suitable for transdermal administration. A further object of the present invention is to provide dermatological or cosmetic compositions characterized by the fact that they contain an amount of sphingomyeUnase effective for producing an increase in the level of ceramides in the skin or mucosa. According to the invention, the sphingomyeUnase contained in such compositions is preferably extracted from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof. Lactic bacteria should preferably be chosen from among the following: Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cello- biosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Steptococcus lactis, Streptococcus raffinolactis and Streptococcus thermophilus. According to a preferred embodiment of the invention the ceUs contained in the compositions are in the form of lyophiUzed or sonicated ceUs. The dermatological or cosmetic compositions of the invention shall preferably comprise from 1 x 10 2 to 1 x 10 15 CFU of lactic bacteria per gram of composition. The dermatological or cosmetic composition of the invention may also contain exogenous ceramide or products containing exogenous ceramide, sphingomyeUnes, fatty acids, cholesterol, ceramidase inhibitors, protease inhibitors, immunomodulators, vitamins, growth factors, surfactants, emulsifiers, stabiUzers, Upids, rheological additives, humidifiers, antioxidants, preservatives, colouring agents, lakes, pigments, auxiliary substances (e.g. acids, bases, propeUants) and functional substances (astringents, antiseborrhoeic agents, anti- dandruff agents, deodorants, skin purifiers, keratogenous agents, moisturizers, anti-xerosis agents, smoothing agents, screens, sunscreens, pigmenting agents, antidepigmenting agents, emolUents, restorers, eutrophic agents, anti-wrinkle agents, antiradicals, stiffeners, anti-stretch-mark agents, vasoprotectors, anti-skin-rash agents, soothing agents, anti-ceUuUtis agents, tonifying agents, stimulants, hypereluting agents, epilators, nail protectors). Lastly, the dermatological or cosmetic compositions of the invention can be formulated in the form of Uquid, semiliquid, semisoUd, soUd or powder products, e.g. in the form of creams, ointments, lotions, capsules, pearls, ovules, mascara, eyewashes, toothpaste, mouth- washes, Upsticks, Uposomes, soap, shaving soap, tonics, douches, enteroclysis solutions, shampoos, anti-dandruff preparations, impregnated and/or medicated bandage or gauze, patches, medicated emulsions, transdermal gels or patches. To confirm the abiUty of these bacteria to induce the generation of ceramide in the skin, the following experiment was conducted, based on the detection of neutral sphingomyeUnase, the enzyme responsible for generating ceramide in human skin. Methods Assay of neutral and acid sphingomyeUnase in lactic bacteria 10 mg of lyophiUzed Streptococcus thermophilus were resuspended in 500 μl of buffer containing HEPES 20 mM, pH 7.4, MgCb 10 mM, EDTA 2 mM, DTT 5 mM, NA3VO4 0.1 mM, Na 2 Mo0 4 0.1 mM, p- nitrophenylphosphate 30 mM, β-glycerophosphate 10 mM, ATP 750 mM, PMSF 1 μM, leupeptin 10 μM, pepstatin 10 μM (Sigma Chemical Co.) and 0.2% Triton X-100 (for the assay of neutral SMase activity) or 500 μl of 0.2% Triton X-100 (for the assay of acid SMase activity). The samples thus prepared were then submitted to lysis by sonication (for 1 min and 50 sec, alternating 10 sec of sonication with 10 sec of rest) using VibraceU sonicator (Sonic and Materials Inc., Danbury, CT). The sonicated samples were then centrifuged for 30 min at 14,000 rpm, at 4°C, the supernatant was removed and the protein concentration determined using the Bio-Rad Laboratories kit (Richmond, CA). 100 μg of sample were incubated for 2 hours at 37°C in a buffer (50 μl final volume) containing HEPES 20 mM, MgCl 2 1 mM, pH 7.4, and 2.25 μl of [N-methyl- 14 C]sphingomyeUn (SM) (0.2 μCi/ml, a.s. 56.6 mCi/mmol, Amersham). To measure the activity of acid sphingomyeUnase, 100 μg of bacterial lysate were incubated for 2 hours at 37°C in a buffer (50 μl final volume) containing sodium acetate 250 mM, EDTA 1 mM, pH 5.0, and 2.25 μl of [N-methyl- 1 C]SM. The reaction was blocked by the addition of 250 μl of chloroform:methanol: acetic acid (4:2:1). The phosphoUpids were extracted, analysed on plates by TLC and hydrolysis of SM quantified by means of autoradiography and Uquid scintillation. The SMase present in the sonicated bacteria was indicated as Units/mg protein. One unit of neutral SMase hydrolyses 1 μmole of sphingo- myeUn per min at pH 7.4 at 37°C. One unit of acid SMase hydrolyzes 1 nmole of SM to N-acetylsphingosine and choUne phosphate per hour at pH 5.0 at 37°C. Preparation of a cream and treatment (duration and modaUtv) A cream was prepared (using a dehydrating base cream) containing sonicated lactic bacteria [2 20-g tubes of base cream plus 1 vial of sonicated lactic bacteria (1 x 10 12 CFU) in 20 ml of water] and the effect of daily appUcations of the cream on the ceramide levels of the horny layer of the epidermis of the forearm was assayed in 8 volunteers as indicated in Table 1 here below. Table 1 No. Sex Age 1 male 45 2 female 39 3 female 29 4 female 27 5 female 33 6 female 32 7 male 38 8 female 25 The subjects were instructed to self- administer the control cream and the experimental cream containing the lactic bacteria twice per day (approximately 1 ml, morning and evening). The control cream was appUed daily on the right forearm, while the experimental cream was appUed on the left forearm. Both creams were rubbed in until they were fully absorbed. Lipids of the horny layer of the epidermis were coUected from the forearm by washing with 250 ml of 99.5% ethanol prior to the start of apphcation of the cream (TO) and one week (Tl) after the start of treatment. The ethanol extracts were concentrated with a rotary evaporator and then evaporated dry. The dried samples were dissolved in 2 ml of chloroform, dried with nitrogen and subjected to DAG kinase assay for ceramide quantification (Amersham, Buckinghamshire, Great Britain). After three extraction runs, the Upids were dried again with nitrogen, dissolved in 100 μl of chloroform and subjected to thin layer chromatography (TLC), using chloroform: methanoLacetic acid (65: 15:5, v/v/v) as the run solvent. Phosphorylated ceramide was detected by autoradiography. The patches corresponding to ceramide- 1 -phosphate were cut and subjected to a count of the radioactivity present using scintillation Uquid in a β-counter. The amount of ceramide present was determined on the basis of a standard curve obtained with authentic ceramide (type III; of bovine brain; Sigma Chemical Co., St. Louis, MO). Results SphingomyeUnase activity in lactic bacteria The levels of neutral sphingomyeUnase activity in the sonicated lactic bacteria samples were approximately 2 x 10 -7 units/mg of bacteria. No acid sphingomyeUnase activity was detected. Effects of sonicated Lactobacillus on ceramide levels in the skin The ceramide levels in the ethanol extracts obtained as described in the "Methods" section are given in Table 2 here below and the respective autoradiographs are shown in Figure 1. It can be noted, regardless of the substantial subjective basal variability, that the use of both creams gave rise to an increase in ceramide levels in the forearm skin of aU the subjects analyzed. However, the increase was much more marked and significant after apphcation of the cream containing lactic bacteria. What is more, the effect of the experimental cream on ceramide levels could be detected earUer compared to that induced by the base cream, thus indicating faster action of the former. Table 2 No. Right forearm Left forearm TO Tl TO Tl 1 0 0 0 1,941 2 223 567 147 298 3 8 500 24.. > 700 4 8 347 2 300 5 300 500 435 1,390 6 400 480 236 340 7 30 28 180 270 10 280 12 278

Claims: Claims 1. Use of sphingomyeUnase for producing dermatological and/or cosmetic compositions suitable to be topically appUed, to increase the levels of skin and mucosal ceramides. 2. Use of sphingomyeUnase for producing dermatological compositions suitable to be topicaUy appUed for the prevention or therapeutical treatment of atopic eczema, dermatosis and dermatitis, in particular atopic dermatitis, psoriasis, ichthyosis, Fabry's disease, Gaucher's disease, Tay-Sachs disease and Sjδgren-Larsson's syndrome. 3. Use of claim 1 or 2, characterized in that the sphingomyeUnase is obtained from Gram-positive bacteria, Gram-negative bacteria, lactic bacteria or mixtures thereof. 4. The use of claim 3, characterized in that the lactic bacteria are selected from the group comprising Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cellobiosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Steptococcus lactis, Streptococcus raffinolactis and Streptococcus thermophilus. 5. Use of sphingomyeUnase as cutaneous permeation or absorption enhancer for preparing pharmaceutical or cosmetic compositions suitable for transdermal administration. 6. The use of any of the preceding claims, characterized in that sphingomyeUnase is used in the form of lyophiUzed or sonicated ceUs. 7. A dermatological or cosmetic composition characterized in that it comprises an amount of sphingomyeUnase effective for bringing about an increase in the level of skin and mucosal ceramides. 8. The composition of claim 7, characterized in that the sphingomyeUnase is obtained from Gram-positive bacteria, Gram- negative bacteria, lactic bacteria or mixtures thereof. 9. The composition of claim 8, characterized in that the lactic bacteria are selected from the group comprising Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cellobiosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus jensenii, Lactobacillus leichmanii, Lactobacillus minutus, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Steptococcus lactis, Streptococcus raffinolactis and Streptococcus thermophilus. 10. The composition of claims 7, 8 or 9, characterized in that sphingomyeUnase is in the form of lyophiUzed or sonicated ceUs. 11. The composition of any one of claims 7-10, characterized in that it comprises from lxlO 2 to lxlO 15 lactic bacteria/gram of composition. 12. The composition of any one of claims 7-11, characterized in that it further comprises exogenous ceramide or products containing exogenous ceramide, sphingomyeUnes, fatty acids, cholesterol, ceramidase inhibitors, protease inhibitors, immunomodulators, vitamins, growth factors, surfactants, emulsifiers, stabiUsers, Upids, rheological additives, humidifiers, antioxidants, preservatives, colouring agents, lakes, pigments, auxiUary substances (e.g. acids, bases, propeUants) and functional substances (astringents, antiseborrhoeic agents, anti-dandruff agents, deodorants, skin purifiers, keratogenous agents, moisturisers, anti-xerosis agents, smoothing agents, screens, sunscreens, pigmenting agents, anti- depigmenting agents, emollients, restores, eutrophic agents, anti- wrinkle agents, antiradicals, stiffeners, anti-stretch-mark agents, vasoprotectors, anti-skin-rash agents, soothing agents, anti-ceUuUtis agents, tonifying agents, stimulants, hypereluting agents, epilators, nail protectors). 13. The composition of any one of claims 7-12 in the form of creams, ointments, lotions, capsules, pearls, ovules, mascara, eyewashes, toothpaste, mouthwashes, Upsticks, Uposomes, soap, shaving soap, tonics, douches, enteroclysis solutions, shampoos, anti-dandruff preparations, impregnated and/or medicated bandage or gauze, patches, medicated emulsions, transdermal gels or patches.

Inventors: CAVALIERE WIDOW VESELY RENATA, DE SIMONE CLAUDIO, CAVALIERE, WIDOW VESELY, RENATA, MARIA, ANNA, DE SIMONE, CLAUDIO
Applicants: CAVALIERE WIDOW VESELY RENATA, SIMONE CLAUDIO DE, CAVALIERE, WIDOW VESELY, RENATA, MARIA, ANNA, DE SIMONE, CLAUDIO
Application year: 1997
Main classification: A61K7
IPC codes: A61K8, A61K38, A61P17, A61Q1, A61Q11, A61Q19